On May 28, 2018, at the opening of a five day to talks at the 36th WIPO Standing Committee on Copyright and Related Rights (SCCR), 11 civil society and library groups sent a letter to negotiators expressing deep concerns over… Continue Reading
The below are comments were filed by KEI and HealthGap on May 22, 2018, regarding a proposed NIH exclusive license on patents for the treatment and diagnosis of Crohn’s Disease, Ulcerative Colitis, Asthma, Psoriasis and Biliary Cirrhosis to Precision IBD… Continue Reading
On May 18, 2018 KEI requested that the Department of Health and Human Services (HHS) investigate the failure to disclose National Institutes of Health (NIH) funding in four patents on Vizamyl (INN flutemetamol F 18), which is used to evaluate… Continue Reading
On Wed, May 16, 2018, the House Ways & Means Committee held a markup on HR. 5773, a bill dealing with the opioid crisis, which would require Medicare prescription drug plans to establish drug management programs for at-risk beneficiaries. Representative… Continue Reading
These are provisions on the right to be forgotten in the European Union’s General Data Protection Regulation (GDPR). (KEI does not support the right to be forgotten). http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32016R0679&from=EN REGULATION (EU) 2016/679 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of… Continue Reading
In advance of the 71st World Health Assembly (21 May 2018 – 26 May 2018), the World Health Organization (WHO) published a document (A71/INF./2, 19 April 2018) entitled, Voluntary contributions by fund and by contributor, 2017. Total voluntary contributions to… Continue Reading
On 14 February 2018 and 16 February 2018, the World Trade Organization (WTO) conducted a Trade Policy Review (TPR) of Malaysia. All members of the WTO are subject to review under the Trade Policy Review Mechanism (TPRM). The TPRM takes… Continue Reading
In a 2-1 ruling, the Court of Appeals for the Fourth Circuit has ruled that Maryland’s 2017 price-gouging law (HB 631) is unconstitutional. The law (Md. Code Ann., Health–General §§ 2-801 et seq.) had prohibited price gouging (defined as an… Continue Reading
FOR IMMEDIATE RELEASE April 5, 2018 kim.treanor@keionline.org (202)-332-2670 Six organizations are asking Department of Health and Human Services Secretary Alex Azar to take actions to lower the price of eteplirsen, a drug sold under the brand name Exondys 51, to… Continue Reading
KEI has submitted a request to Mr. James Carroll, Acting Director of the Office of National Drug Control Policy, and to Ms. Kellyanne Conway, Counselor to the President and appointed “opioid czar,” asking that the federal government use its authority… Continue Reading